4-(4-(cyclopentyloxy)quinolin-2-yl)benzene-1,2-diol manufacturers
- CMS-121
-
-
2026-08-25
- CAS:1353224-53-9
- Min. Order: 1bag
- Purity: 98%
- Supply Ability: 1000
- CMS121
-
- $3.00
-
2026-08-25
- CAS:1353224-53-9
- Purity: 99%
|
| | 4-(4-(cyclopentyloxy)quinolin-2-yl)benzene-1,2-diol Basic information |
| Product Name: | 4-(4-(cyclopentyloxy)quinolin-2-yl)benzene-1,2-diol | | Synonyms: | 1,2-Benzenediol,4-[4-(cyclopentyloxy)-2-quinolinyl]-;4-(4-(cyclopentyloxy)quinolin-2-yl)be nzene-1,2-diol (CMS121);ACC, Acetyl Coenzyme A Carboxylase,disease,neuroprotective,inhibit,anti-inflammatory,mitochondrial,Alzheimer's,antioxidative,acetylation,Inhibitor,H3K9,Acetyl-CoA Carboxylase,CMS 121,dementia,ACC1,CMS-121;CMS-121, 10 mM in DMSO;4-(4-(cyclopentyloxy)quinolin-2-yl)be;CMS-121;CMS-121/4-(4-(cyclopentyloxy)quinolin-2-yl)benzene-1,2-diol | | CAS: | 1353224-53-9 | | MF: | C20H19NO3 | | MW: | 321.37 | | EINECS: | | | Product Categories: | CMS121;API | | Mol File: | 1353224-53-9.mol |  |
| | 4-(4-(cyclopentyloxy)quinolin-2-yl)benzene-1,2-diol Chemical Properties |
| Boiling point | 511.0±50.0 °C(Predicted) | | density | 1.297±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 30 mg/ml; DMSO: 20 mg/ml | | form | A crystalline solid | | pka | 8.53±0.20(Predicted) | | color | Light yellow to yellow | | InChI | InChI=1S/C20H19NO3/c22-18-10-9-13(11-19(18)23)17-12-20(24-14-5-1-2-6-14)15-7-3-4-8-16(15)21-17/h3-4,7-12,14,22-23H,1-2,5-6H2 | | InChIKey | OMHNVUCFPJJLKD-UHFFFAOYSA-N | | SMILES | C1(O)=CC=C(C2C=C(OC3CCCC3)C3C(N=2)=CC=CC=3)C=C1O |
| | 4-(4-(cyclopentyloxy)quinolin-2-yl)benzene-1,2-diol Usage And Synthesis |
| Uses | CMS-121 is a quinolone derivative and an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor. CMS-121 protects HT22 cells against ischemia and oxidative damage with EC50 values of 7 nM and 200 nM, respectively. CMS-121 has strong neuroprotective, anti-inflammatory, antioxidative and renoprotective activities[1][2][3]. | | in vivo | CMS-121 (~20 mg/kg; oral administration; daily; for 4 months; female SAMP8 mice) treatment reduces cognitive decline as well as metabolic and transcriptional markers of aging in the brain when administered to rapidly aging SAMP8 mice. CMS-121 preserves mitochondrial homeostasis by regulating acetyl-coenzyme A (acetyl-CoA) metabolism[1]. | Animal Model: | Female SAMP8 mice (9 months old)[1] | | Dosage: | ~20 mg/kg/day | | Administration: | Oral administration; daily; for 4 months | | Result: | Reduced cognitive decline as well as metabolic and transcriptional markers of aging in the brain.
|
| | References | [1] Currais A, et al. Elevating acetyl-CoA levels reduces aspects of brain aging. Elife. 2019 Nov 19;8. pii: e47866. DOI:10.7554/eLife.47866
[2] Chiruta C, et al. Chemical modification of the multitarget neuroprotective compound fisetin. J Med Chem. 2012 Jan 12;55(1):378-89. DOI:10.1021/jm2012563
[3] Prior M, et al. Back to the future with phenotypic screening. ACS Chem Neurosci. 2014 Jul 16;5(7):503-13. DOI:10.1021/cn500051h |
| | 4-(4-(cyclopentyloxy)quinolin-2-yl)benzene-1,2-diol Preparation Products And Raw materials |
|